ProCE Banner Activity

Evaluating and Managing High-Risk Disease in HR+/HER2- EBC (Without gBRCA)


Get up to date on assessing risk and selecting among perioperative treatment options for patients with high-risk HR+/HER2- early breast cancer with wild-type BRCA status.

Released: June 01, 2023



Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

ProCE Banner


Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.


Merck Sharp & Dohme, LLC